Article Text

Download PDFPDF
Telmisartan and ramipril were equivalent, but their combination increased adverse events in vascular disease or diabetes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Source of funding: Boehringer Ingelheim; Heart and Stroke Foundation of Ontario; Canadian Institutes of Health Research.